Jagged Ends of Urinary Cell-Free DNA Assessed in Bladder Cancer Detection
By LabMedica International staff writers Posted on 27 May 2021 |

Image: Schematic of workflow for urinary DNA jagged end analysis. Urinary DNA was subjected to an end-repair process; JI-U = jagged index–unmethylated (Photo courtesy of The Chinese University of Hong Kong)
Bladder cancer is where a growth of abnormal tissue, known as a tumor, develops in the bladder lining. In some cases, the tumor spreads into the bladder muscle. The most common symptom of bladder cancer is blood in the urine, which is usually painless.
Cell-free DNA (cfDNA) molecules in plasma consist of fragments of DNA. Much interest has been focused recently on the fragmentation patterns of such DNA molecules. The fragment sizes and ends, for example, display nucleosomal features in relation to the tissues of origin. When compared with plasma DNA, urinary cfDNA molecules exhibit a different size profile; therefore, urinary DNA molecules are much more fragmented than plasma DNA.
Medical Scientists at The Chinese University of Hong Kong (Shatin, Hong Kong, China) and their colleagues obtained bisulfite sequencing data of urinary DNA from a previous study, including 46 patients with bladder cancer, all of whom were urothelial cell carcinoma, and 39 control participants with hematuria, but without detectable bladder cancer. Among patients with bladder cancer, 37 had non–muscle-invasive bladder cancer and nine patients with muscle-invasive bladder cancer.
Urinary cfDNA was extracted using the Wizard Plus Minipreps DNA Purification System (Promega, Madison, WI, USA) with the addition of guanidine thiocyanate to urine before mixing with resin. DNA libraries were sequenced using the Illumina HiSeq 2500 or NextSeq 500 with a 41 bp × 2 paired-end sequencing protocol (Illumina, San Diego, CA, USA). Incorporation of unmethylated cytosines during the repair of the jagged ends lowered the apparent methylation levels measured by bisulfite sequencing and were used to calculate a jagged end index. This approach is called jagged end analysis by sequencing.
The investigators reported that the jagged end index of urinary cfDNA was higher than that of plasma DNA. The jagged end index profile of plasma DNA displayed several strongly oscillating major peaks at intervals of approximately 165 bp (i.e., nucleosome size) and weakly oscillating minor peaks with periodicities of approximately 10 bp. In contrast, the urinary DNA jagged end index profile showed weakly oscillating major peaks, but strongly oscillating minor peaks. The jagged end index was generally higher in nucleosomal linker DNA regions. The 46 Patients with bladder cancer had lower jagged end indexed of urinary DNA than 39 participants without bladder cancer. The area under the curve for differentiating between patients with and without bladder cancer was 0.83.
The authors concluded that jagged ends represent a property of urinary cfDNA. The generation of jagged ends might be related to nucleosomal structures, with enrichment in linker DNA regions. Jagged ends of urinary DNA could potentially serve as a new biomarker for bladder cancer detection. The study was published in the April, 2021 issue of the journal Clinical Chemistry.
Related Links:
The Chinese University of Hong Kong
Promega
Illumina
Cell-free DNA (cfDNA) molecules in plasma consist of fragments of DNA. Much interest has been focused recently on the fragmentation patterns of such DNA molecules. The fragment sizes and ends, for example, display nucleosomal features in relation to the tissues of origin. When compared with plasma DNA, urinary cfDNA molecules exhibit a different size profile; therefore, urinary DNA molecules are much more fragmented than plasma DNA.
Medical Scientists at The Chinese University of Hong Kong (Shatin, Hong Kong, China) and their colleagues obtained bisulfite sequencing data of urinary DNA from a previous study, including 46 patients with bladder cancer, all of whom were urothelial cell carcinoma, and 39 control participants with hematuria, but without detectable bladder cancer. Among patients with bladder cancer, 37 had non–muscle-invasive bladder cancer and nine patients with muscle-invasive bladder cancer.
Urinary cfDNA was extracted using the Wizard Plus Minipreps DNA Purification System (Promega, Madison, WI, USA) with the addition of guanidine thiocyanate to urine before mixing with resin. DNA libraries were sequenced using the Illumina HiSeq 2500 or NextSeq 500 with a 41 bp × 2 paired-end sequencing protocol (Illumina, San Diego, CA, USA). Incorporation of unmethylated cytosines during the repair of the jagged ends lowered the apparent methylation levels measured by bisulfite sequencing and were used to calculate a jagged end index. This approach is called jagged end analysis by sequencing.
The investigators reported that the jagged end index of urinary cfDNA was higher than that of plasma DNA. The jagged end index profile of plasma DNA displayed several strongly oscillating major peaks at intervals of approximately 165 bp (i.e., nucleosome size) and weakly oscillating minor peaks with periodicities of approximately 10 bp. In contrast, the urinary DNA jagged end index profile showed weakly oscillating major peaks, but strongly oscillating minor peaks. The jagged end index was generally higher in nucleosomal linker DNA regions. The 46 Patients with bladder cancer had lower jagged end indexed of urinary DNA than 39 participants without bladder cancer. The area under the curve for differentiating between patients with and without bladder cancer was 0.83.
The authors concluded that jagged ends represent a property of urinary cfDNA. The generation of jagged ends might be related to nucleosomal structures, with enrichment in linker DNA regions. Jagged ends of urinary DNA could potentially serve as a new biomarker for bladder cancer detection. The study was published in the April, 2021 issue of the journal Clinical Chemistry.
Related Links:
The Chinese University of Hong Kong
Promega
Illumina
Latest Molecular Diagnostics News
- New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
- Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
- mNGS CSF Test Outperforms Traditional Microbiological Testing for Infectious Diseases
- Point-Of-Care Test to Transform Early-Stage Cervical Cancer Diagnosis
- PET/ctDNA-Guided Approach Helps Determine Lymphoma Treatment
- Next-Generation 'Agnostic Diagnostics' to Detect Respiratory Viruses at POC
- First-Ever Test of Cure for Chagas Disease Determines Treatment Effectiveness
- Capsule Sponge Test Could Replace Endoscopies for Monitoring Esophageal Cancer Risk
- Nasal Swab Test Offers Simpler and Less Costly Virus Screening in High-Risk Settings
- DNA Test Accurately Predicts Resistance to Common Chemotherapy Treatments
- Umbilical Cord Blood Test Can Detect Early Sepsis in Preterm Infants
- Simple Blood Test Predicts Cognitive Decline in Alzheimer's Patients
- Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer
- Portable CRISPR-Based Molecular Technology Brings Highly Accurate Diagnostics to Point of Need
- Palm-Sized Device Detects Disease-Related Genetic Material In 45 Minutes
- Advanced Computational Tool Paves Way for Diagnostic Tests to Detect Hidden Genetic Mutations
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read moreTechnology
view channel
New POC Biosensing Technology Improves Detection of Molecular Biomarkers
Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation.... Read more
Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists.... Read moreIndustry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more